Table F-2. General characteristics of Bayesian mixed treatment comparisons

| **Author, year****(N authors)** | **Method-ologist\***  | **Country** | **Funding**  | **# printed pages** | **Affiliation** | **Supplement or appendix** | **Disease state evaluated** | **N and type of interventions compared** | **N trials,** **N patients** | **Network pattern** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Baldwin, 2011 (4)† | Yes | UK | Industry | 11 | No | Yes | Behavioral Health (GAD) | 10, Rx | 273,989 | Network with ≥1 closed loop |
| Bangalore,2011 (10) | No | USA | Unfunded | 18 | No | Yes | Cardiology (anti-hypertensives) | 8, Rx | 70324,168 | Network with ≥1 closed loop |
| Gross, 2011(9) | No | Brazil | Government/foundation | 8 | No | Yes | Endocrinology (T2DM) | 6, Rx | 184,535 | Network with ≥1 closed loop |
| Hartling, 2011(8) | Yes | Canada, Portugal | Government/foundation | 10 | No | Yes | Respiratory (acute bronchiolitis) | 7, Rx | 484897 | Network with ≥1 closed loop |
| Maund, 2011 (6) | No | UK | Government/foundation | 6‡ | HTA | Yes | Pain (major surgery) | 4, Rx | 605,236 | Network with ≥1 closed loop |
| Sciarretta, 2011 (5) | Yes | Italy | NR | 11 | No | No | Cardiology (HTN and heart failure) | 8, Rx | 26223,313 | Network with ≥1 closed loop |
| Trelle, 2011(8) | Yes | Switzerland | Government/foundation | 11 | No | Yes | Pain (NSAIDs) | 8, Rx | 31116,429 | Network with ≥1 closed loop |
| van de Kerkhof, 2011 (4) | No | UK | Industry | 13 | No | Yes | Dermatology (psoriasis) | 17, Rx | 199,134 | Network with ≥1 closed loop |
| van den Bruel, 2011 (6) | No | Belgium | Unfunded | 6 | No | No | Opthamology (cataract surgery) | 6, Devices | 211,769 | Network with ≥1 closed loop |
| Dakin, 2010 (3) | Yes | UK | Industry | 12 | No | Yes | Gastroenterology (chronic hepatitis B) | 8, Rx | 233,702 | Network with ≥1 closed loop |
| Orme, 2010 (5) | No | UK | Industry | 18 | No | Yes | Opthamology (glaucoma) | 10, Rx||19, Rx | 9316,898 | Network with ≥1 closed loop |
| Phung, 2010 (4) | No | USA | Government/foundation | 9 | No | Yes | Endocrinology (T2DM) | 7, Rx | 2711,198 | Network with ≥1 closed loop |
| Uthman, 2010 (2) | Yes | UK | NR | 7 | No | No | Behavioral Health (anxiety) | 6, Rx | 16IC | Network with ≥1 closed loop |
| Vissers, 2010 (5) | No | Netherlands | Industry | 9 | No | No | Pain (cancer) | 5, Rx | 6594 | Network with ≥1 closed loop§ |
| Walsh, 2010 (6) | No | UK | Government/foundation | 221¶ | Cochrane | No | Dental | 7, Rx | 75105,969 | Network with ≥1 closed loop |
| Wandel, 2010(8) | Yes | Switzerland | Government/foundation | 9 | No | No | Rhuematology(OA)  | 4, Rx | 103,803 | Network with ≥1 closed loop |
| Wang, 2010 (9) | No | China | Government/foundation | 11 | No | No | Infectious Disease (CVCs for infections) | 10, Device | 4811,525 | Network with ≥1 closed loop |
| Woo, 2010 (10) | No | Canada | Industry | 12 | No | Yes | Gastroenterology (chronic hepatitis B) | 10, Rx | 208,624 | Network with ≥1 closed loop§ |
| Baker, 2009 (3) | No | USA | NR | 15 | No | No | Pulmonology (COPD) | 5, Rx | 4331,020 | Network with ≥1 closed loop§ |
| Bansback, 2009 (6) | Yes | Canada | Industry | 10 | No | No | Dermatology (psoriasis) | 8, Rx | 229,917 | Network with ≥1 closed loop§ |
| Cipriani, 2009 (12) | Yes | Italy | Unfunded | 13 | No | No | Behavioral Health (depression) | 12, Rx | 11725,928 | Network with ≥1 closed loop |
| Edwards, 2009a (4) | No | UK | Industry | 10 | No | No | Gastroenterology (erosive esophagitis) | 5, Rx | 125,181 | Network with ≥1 closed loop |
| Edwards, 2009b (2) | No | UK | Industry | 14 | No | Yes | Behavioral Health (bipolar and schizophrenia) | 5, Rx | 48NR | Network with ≥1 closed loop |
| Golfinopoulos, 2009 (6) | Yes | Greece | NR | 4 | No | Yes | Oncology (unknown primary site) | 5, Rx | 10683 | Network with ≥1 closed loop§ |
| Manzoli, 2009 (6) | Yes | Italy | NR | 11 | No | Yes | Infectious disease (avian flu vaccine) | 13, Other | 138,382 | Network with ≥1 closed loop |
| Meader, 2009(1) | No | UK | Unknown | 5 | No | Yes | Substance Absuse(opiod detoxification) | 4, Rx | 202,112 | Network with ≥1 closed loop§ |
| Coleman, 2008 (4) | No | USA | NR | 8 | No | No | Cardiology (anti-hypertensives) | 6, Rx | 27126,137 | Network with ≥1 closed loop |
| Mauri, 2008 (5) | Yes | Greece | Unfunded | 12 | No | Yes | Oncology (breast cancer) | 22, Rx | 12826,031 | Network with ≥1 closed loop |
| Stettler, 2008 (29) | Yes | Switzerland | Government/foundation | 11 | No | Yes | Cardiology (stents) | 3, Device | 3514,799 | Closed loop§ |
| Golfinopoulos, 2007 (4) | Yes | Greece | Unfunded | 14 | No | Yes | Oncology (colorectal cancer) | 12, Rx | 4015,802 | Network with ≥1 closed loop |
| Lam, 2007 (2) | No | China | Unfunded | 10 | No | No | Cardiology (left ventricular dysfunction) | 5, Device and Rx | 128,307 | Network with ≥1 closed loop |
| Nixon, 2007(3) | Yes | UK | Other | 8 | No | No | Rheumatology(RA) | 9, Rx | 136,694 | Network with ≥1 closed loop§ |
| Cooper, 2006 (4) | No | England | Government/foundation | 7 | No | Yes | Cardiology (stroke prevention) | 8, Rx | 1917,833 | Network with ≥1 closed loop |
| Kyrgiou, 2006 (5) | Yes | Greece | NR | 9 | No | Yes | Oncology (ovarian cancer) | 8, Rx | 6016,478 | Network with ≥1 closed loop§ |

Abbreviations: CODP: chronic obstructive pulmonary disease; CVC: central venous catheter; DM: diabetes mellitus; HTA: Health Technology Assessment; HTN: hypertension; NSAID: non-steroidal anti-inflammatory drugs; RA: rheumatoid arthritis; RCC: renal cell carcinoma; RLS: restless leg syndrome; Rx: pharmacologic; T2DM: type 2 diabetes mellitus;

\*: A methodologist was considered an individual with affiliation to a department of statistics, biostatistics, epidemiology, clinical epidemiology, or public health services, as determined by author information and affiliations listed in the publication.

†: Includes both a Bayesian MTC model and a Frequentist MTC model therefore appears in both tables.

‡: Published as a manuscript and report, with the manuscript serving as the primary data source.

§: Diagram was not provided, pattern determined from study characteristics reported

||: Two models reported

¶: Cochrane report